Treatment and outcome of secondary AD in all patients having received autologous HSCT for a primary AD
Original AD . | Secondary AD . | No. of patients . | Treatment of AD . | Status of secondary AD at last follow-up . |
---|---|---|---|---|
SLE | AIHA | 1 | Prednisone, cyclophosphamide, rituximab | Resolved |
SSc | AIHA | 1 | None | Resolved |
MS | Hemophilia | 1 | Prednisone, cyclophosphamide, IVIg, RTX, novo 7 | Dead |
MS | Hemophilia | 1 | Prednisone, cyclophosphamide, cyclosporine, IVIg, PE | Resolved |
SLE | Hemophilia | 1 | Prednisone, cyclophosphamide, IVIg, PE, RTX | Resolved |
SSc | ITP | 1 | Prednisone | Resolved |
MS | ITP | 1 | Prednisone | Resolved |
MS | ITP/AIHA | 1 | Prednisone, MMF, IVIg, rituximab | Ongoing with therapy until dead (HSCT related) |
1 SLE/1 SSc | Antiphospholipid syndrome | 2 | Steroids/none | Resolved/dead |
1 JIA | Thyroiditis | 1 | Unknown | Unknown |
1 JIA/1 IDD | Thyroiditis | 2 | None/L-thyroxine | Ongoing without treatment |
1 SSc, 3 MS 1 JIA, 1 SLE | Thyroiditis | 6 | L-thyroxine or thyrostatic therapy | Ongoing with therapy |
1 MS | Thyroiditis | 1 | L-thyroxine | Resolved |
SSc | Blocking TSHR antibody | 1 | None | Ongoing without therapy |
SSc | Graves disease | 1 | Carbimazole | Ongoing with therapy |
SLE | Graves disease | 1 | Thyroidectomy | Resolved |
SSc | Myasthenia gravis | 1 | MMF | Ongoing with therapy |
SSc | Rheumatoid arthritis | 1 | Methotrexate, abatacept | Ongoing with therapy |
SSc | Rheumatoid arthritis | 1 | NSAIDs | Ongoing without therapy |
JIA | Sarcoidosis | 1 | Prednisone, methotrexate | Ongoing with therapy |
JIA | Sarcoidosis | 1 | Prednisone | Resolved |
RA | Psoriasis | 1 | None | Ongoing without therapy |
Original AD . | Secondary AD . | No. of patients . | Treatment of AD . | Status of secondary AD at last follow-up . |
---|---|---|---|---|
SLE | AIHA | 1 | Prednisone, cyclophosphamide, rituximab | Resolved |
SSc | AIHA | 1 | None | Resolved |
MS | Hemophilia | 1 | Prednisone, cyclophosphamide, IVIg, RTX, novo 7 | Dead |
MS | Hemophilia | 1 | Prednisone, cyclophosphamide, cyclosporine, IVIg, PE | Resolved |
SLE | Hemophilia | 1 | Prednisone, cyclophosphamide, IVIg, PE, RTX | Resolved |
SSc | ITP | 1 | Prednisone | Resolved |
MS | ITP | 1 | Prednisone | Resolved |
MS | ITP/AIHA | 1 | Prednisone, MMF, IVIg, rituximab | Ongoing with therapy until dead (HSCT related) |
1 SLE/1 SSc | Antiphospholipid syndrome | 2 | Steroids/none | Resolved/dead |
1 JIA | Thyroiditis | 1 | Unknown | Unknown |
1 JIA/1 IDD | Thyroiditis | 2 | None/L-thyroxine | Ongoing without treatment |
1 SSc, 3 MS 1 JIA, 1 SLE | Thyroiditis | 6 | L-thyroxine or thyrostatic therapy | Ongoing with therapy |
1 MS | Thyroiditis | 1 | L-thyroxine | Resolved |
SSc | Blocking TSHR antibody | 1 | None | Ongoing without therapy |
SSc | Graves disease | 1 | Carbimazole | Ongoing with therapy |
SLE | Graves disease | 1 | Thyroidectomy | Resolved |
SSc | Myasthenia gravis | 1 | MMF | Ongoing with therapy |
SSc | Rheumatoid arthritis | 1 | Methotrexate, abatacept | Ongoing with therapy |
SSc | Rheumatoid arthritis | 1 | NSAIDs | Ongoing without therapy |
JIA | Sarcoidosis | 1 | Prednisone, methotrexate | Ongoing with therapy |
JIA | Sarcoidosis | 1 | Prednisone | Resolved |
RA | Psoriasis | 1 | None | Ongoing without therapy |
MMF indicates mycophenolate mofetil; IVIg, intravenous immunoglobulin; PE, plasma exchange; NSAIDs, nonsteroidal anti-inflammatory drugs; RTX, rituximab; TSHR, thyroid stimulating hormone receptor; MS, multiple sclerosis; SSc, systemic sclerosis; and JIA, juvenile idiopathic arthritis.